September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Application of CRISPR/Cas9 to the study and treatment of retinal disease
Author Affiliations & Notes
  • Donald J Zack
    Wilmer Eye Inst, Johns Hopkins Univ, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Donald Zack, Bayer (F), Intellia (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Donald J Zack; Application of CRISPR/Cas9 to the study and treatment of retinal disease. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Challenges remain, but CRISPR/Cas9 technology is rapidly moving toward potential clinical development. This presentation will highlight some of the targets that are being pursued in the retina and technological advances that may assist the translation of this exciting technology into a viable therapeutic approach.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.